FUSN Fusion Pharmaceuticals Inc. Stock Quote

FUSN [NASD]

Index	-	P/E	-	EPS (ttm)	-	Insider Own	9.03%	Shs Outstand	41.68M	Perf Week	-11.76%
Market Cap	475.06M	Forward P/E	-	EPS next Y	-0.44	Insider Trans	-0.22%	Shs Float	31.91M	Perf Month	-8.46%
Income	-	PEG	-	EPS next Q	-0.22	Inst Own	76.20%	Short Float	1.28%	Perf Quarter	-8.31%
Sales	-	P/S	-	EPS this Y	-38.90%	Inst Trans	0.16%	Short Ratio	7.30	Perf Half Y	-13.12%
Book/sh	7.35	P/B	1.53	EPS next Y	73.70%	ROA	-	Target Price	-	Perf Year	-
Cash/sh	6.92	P/C	1.63	EPS next 5Y	-	ROE	-	52W Range	11.21 - 19.00	Perf YTD	-4.17%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-40.74%	Beta	-
Dividend %	-	Quick Ratio	55.90	Sales past 5Y	-	Gross Margin	-	52W Low	0.45%	ATR	0.70
Employees	41	Current Ratio	55.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	37.80	Volatility	6.00% 5.47%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-189.00%	Profit Margin	-	Rel Volume	0.88	Prev Close	11.63
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	55.94K	Price	11.26
Recom	1.60	SMA20	-6.45%	SMA50	-9.71%	SMA200	-13.99%	Volume	49,322	Change	-3.18%

Jul-21-20

Initiated

Wedbush

Outperform

$25

Jul-21-20

Initiated

Jefferies

Buy

$25

Jul-21-20

Initiated

Cowen

Outperform

Jan-25-21 12:40AM	Fusion Pharmaceuticals (NASDAQ:FUSN) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Jan-22-21 01:39PM	Cosmo Music and Music Tribe to Enter Super Partner Relationship CNW Group
Jan-11-21 07:30AM	/R E P E A T -- Media Advisory - CRTC to Hold a Virtual Hearing in Gatineau, Quebec/ CNW Group
Dec-16-20 09:00AM	TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope GlobeNewswire
Dec-10-20 06:24PM	Is FUSN A Good Stock To Buy Now? Insider Monkey
08:10AM	Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors PR Newswire
08:10AM	Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors CNW Group
Nov-26-20 12:36AM	What Is The Ownership Structure Like For Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)? Simply Wall St.
Nov-12-20 04:10PM	Fusion Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference PR Newswire
04:10PM	Fusion Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference CNW Group
Nov-10-20 07:00AM	Fusion Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update PR Newswire
07:00AM	Fusion Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update CNW Group
Nov-02-20 04:10PM	Fusion Pharmaceuticals Appoints Barbara Duncan as Chairperson of the Board of Directors PR Newswire
07:00AM	Fusion Pharmaceuticals Announces Collaboration with AstraZeneca to Develop and Commercialize Next-Generation Radiopharmaceuticals and Combination Therapies PR Newswire
Oct-27-20 03:30PM	Orion Mine Finance Provides Update of its Ownership of Common Shares of Doré Copper Mining Corp. CNW Group
Sep-29-20 04:15PM	Fusion Pharmaceuticals Appoints Maria Stahl as Chief Legal Officer PR Newswire
Sep-27-20 10:18AM	Should You Take Comfort From Insider Transactions At Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)? Simply Wall St.
Sep-10-20 09:00AM	Fusion Pharmaceuticals to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference PR Newswire
Aug-11-20 07:25AM	Fusion Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update PR Newswire
Aug-05-20 08:00AM	Fusion Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference PR Newswire
Jul-14-20 09:30AM	H1 2020 Canadian IPO - CSE leads in number of non-CPC/SPAC IPOs (88%), GFL IPO accounts 77% of IPO amount CNW Group
Jul-10-20 05:13PM	e.l.f. Beauty, Akouos See Activist Actions Barrons.com
Jun-25-20 10:39PM	Fusion Pharmaceuticals Announces Pricing of Initial Public Offering PR Newswire
10:39PM	Fusion Pharmaceuticals Announces Pricing of Initial Public Offering CNW Group

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ADAMS STREET PARTNERS LLC	10% Owner	Dec 24	Sale	12.32	3,800	46,816	418,190	Dec 29 04:01 PM
ADAMS STREET PARTNERS LLC	10% Owner	Dec 23	Sale	12.39	4,569	56,610	418,645	Dec 28 04:02 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience